Chronic activation of human cardiac fibroblasts in vitro attenuates the reversibility of the myofibroblast phenotype.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
26 07 2023
26 07 2023
Historique:
received:
10
11
2022
accepted:
24
07
2023
medline:
28
7
2023
pubmed:
27
7
2023
entrez:
26
7
2023
Statut:
epublish
Résumé
Activation of cardiac fibroblasts and differentiation to myofibroblasts underlies development of pathological cardiac fibrosis, leading to arrhythmias and heart failure. Myofibroblasts are characterised by increased α-smooth muscle actin (α-SMA) fibre expression, secretion of collagens and changes in proliferation. Transforming growth factor-beta (TGF-β) and increased mechanical stress can initiate myofibroblast activation. Reversibility of the myofibroblast phenotype has been observed in murine cells but has not been explored in human cardiac fibroblasts. In this study, chronically activated adult primary human ventricular cardiac fibroblasts and human induced pluripotent stem cell derived cFbs (hiPSC-cFbs) were used to investigate the potential for reversal of the myofibroblast phenotype using either subculture on soft substrates or TGF-β receptor inhibition. Culture on softer plates (25 or 2 kPa Young's modulus) did not alter proliferation or reduce expression of α-SMA and collagen 1. Similarly, culture of myofibroblasts in the presence of TGF-β inhibitor did not reverse myofibroblasts back to a quiescent phenotype. Chronically activated hiPSC-cFbs also showed attenuated response to TGF-β receptor inhibition and inability to reverse to quiescent fibroblast phenotype. Our data demonstrate substantial loss of TGF-β signalling plasticity as well as a loss of feedback from the surrounding mechanical environment in chronically activated human myofibroblasts.
Identifiants
pubmed: 37495732
doi: 10.1038/s41598-023-39369-y
pii: 10.1038/s41598-023-39369-y
pmc: PMC10372150
doi:
Substances chimiques
Transforming Growth Factor beta
0
Actins
0
Transforming Growth Factor beta1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12137Subventions
Organisme : British Heart Foundation
ID : FS/19/12/34204
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/19/76/34927
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N013913/1
Pays : United Kingdom
Organisme : National Centre for the Replacement, Refinement and Reduction of Animals in Research
ID : NC/T2T0119
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 221650/Z/20/Z
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/15/117/31961
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/19/16/34169
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/N018869/1
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/15/6/31436
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/17/15/33106
Pays : United Kingdom
Organisme : National Centre for the Replacement, Refinement and Reduction of Animals in Research
ID : NC/C013202/1
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/21/10545
Pays : United Kingdom
Organisme : British Heart Foundation
ID : SP/15/9/31605
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CRMR/21/290009
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 109604/Z/15/Z
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/17/55/33087
Pays : United Kingdom
Informations de copyright
© 2023. The Author(s).
Références
Toxicol Sci. 2020 May 1;175(1):24-34
pubmed: 32077954
Circ Res. 2016 Mar 18;118(6):1021-40
pubmed: 26987915
Am J Physiol Heart Circ Physiol. 2010 Jan;298(1):H221-8
pubmed: 19897714
Cardiovasc Res. 2000 May;46(2):257-63
pubmed: 10773229
Am J Physiol Heart Circ Physiol. 2003 Nov;285(5):H1871-81
pubmed: 12842814
J Am Coll Cardiol. 1998 Jul;32(1):187-96
pubmed: 9669269
Circ Res. 2019 Aug 16;125(5):552-566
pubmed: 31288631
J Am Coll Cardiol. 2019 May 14;73(18):2267-2282
pubmed: 31072570
J Mol Cell Cardiol. 2014 May;70:37-46
pubmed: 24412581
Sci Rep. 2021 Jan 12;11(1):617
pubmed: 33436786
Sci Adv. 2018 Jan 17;4(1):eaao4881
pubmed: 29349300
Mol Biol Cell. 2017 Jul 7;28(14):1871-1882
pubmed: 28468977
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
Circulation. 2013 Oct 15;128(16):1810-52
pubmed: 23741057
Am J Physiol Heart Circ Physiol. 2012 Dec 15;303(12):H1385-96
pubmed: 23064834
Sci Rep. 2019 Sep 9;9(1):12889
pubmed: 31501457
PLoS One. 2012;7(7):e39969
pubmed: 22808079
Biotechnol Bioeng. 2010 Apr 15;105(6):1148-60
pubmed: 20014437
Nat Rev Nephrol. 2016 Jun;12(6):325-38
pubmed: 27108839
Hypertension. 2002 Mar 1;39(3):756-60
pubmed: 11897758
Circulation. 2003 Feb 25;107(7):984-91
pubmed: 12600911
Biophys J. 2018 Nov 20;115(10):1966-1980
pubmed: 30473015
Toxicol Pathol. 2011 Oct;39(6):916-24
pubmed: 21859884
Commun Biol. 2021 Jan 29;4(1):146
pubmed: 33514846
J Mol Cell Cardiol. 2014 Nov;76:73-83
pubmed: 25134464
Exp Cell Res. 2011 Aug 1;317(13):1914-21
pubmed: 21440539
Cytokine. 1995 Jul;7(5):389-97
pubmed: 7578976
Circ Res. 2000 Mar 17;86(5):571-9
pubmed: 10720419
J Pathol. 2008 Jan;214(2):199-210
pubmed: 18161745
Circulation. 2005 Feb 15;111(6):774-81
pubmed: 15699264
Am J Physiol Heart Circ Physiol. 2003 Jan;284(1):H176-84
pubmed: 12388314
Clin Cancer Res. 2019 Dec 1;25(23):6976-6985
pubmed: 31481511
J Mol Cell Cardiol. 2016 Feb;91:238-46
pubmed: 26774702
Circulation. 1997 Aug 5;96(3):874-81
pubmed: 9264495
J Am Heart Assoc. 2020 Oct 20;9(19):e017025
pubmed: 32924724
Cell Mol Life Sci. 2019 Nov;76(21):4179-4201
pubmed: 31563998
Circ Res. 2010 Oct 15;107(8):1011-20
pubmed: 20705922
Nat Rev Cardiol. 2017 Aug;14(8):484-491
pubmed: 28436487
Exp Biol Med (Maywood). 2018 Apr;243(7):601-612
pubmed: 29504479
J Am Heart Assoc. 2021 Feb;10(5):e019338
pubmed: 33586463
Sci Rep. 2016 Feb 10;6:20835
pubmed: 26861111
Front Physiol. 2017 Apr 24;8:238
pubmed: 28484397
Circulation. 2020 Nov 10;142(19):1831-1847
pubmed: 32972203
J Clin Invest. 2010 Oct;120(10):3520-9
pubmed: 20811150
Circulation. 2017 Aug 8;136(6):549-561
pubmed: 28356446
Hypertension. 2002 Feb;39(2):258-63
pubmed: 11847194
Cardiovasc Res. 2015 Mar 1;105(3):260-70
pubmed: 25560320
Cell Tissue Res. 2016 Nov;366(2):381-391
pubmed: 27324126
Circulation. 2002 Jul 2;106(1):130-5
pubmed: 12093782
Cardiovasc Res. 2011 Feb 1;89(2):265-72
pubmed: 20880837
Circulation. 2020 Aug 4;142(5):466-482
pubmed: 32403949
Nature. 2020 Dec;588(7838):466-472
pubmed: 32971526
EMBO Mol Med. 2020 Oct 7;12(10):e10865
pubmed: 32955172
Periodontol 2000. 2013 Oct;63(1):14-28
pubmed: 23931051
Circulation. 2017 Aug 8;136(6):e137-e161
pubmed: 28455343
J Clin Invest. 2017 Oct 2;127(10):3770-3783
pubmed: 28891814
Dev Dyn. 2010 Jun;239(6):1573-84
pubmed: 20503355
Chest. 2002 Dec;122(6 Suppl):286S-289S
pubmed: 12475801
Circ Res. 2016 Sep 30;119(8):909-20
pubmed: 27502479
Nat Rev Mol Cell Biol. 2002 May;3(5):349-63
pubmed: 11988769
J Am Soc Hypertens. 2010 May-Jun;4(3):135-41
pubmed: 20470998
Exp Cell Res. 2003 Jan 15;282(2):90-100
pubmed: 12531695
J Mol Cell Cardiol. 2016 May;94:72-81
pubmed: 27017945
Cardiovasc Toxicol. 2015 Oct;15(4):309-23
pubmed: 25488804
Cardiovasc Res. 2017 Apr 01;113(5):464-474
pubmed: 28339646
Heart Fail Rev. 2014 Mar;19(2):173-85
pubmed: 23124941
Am J Physiol Heart Circ Physiol. 2005 Mar;288(3):H1131-8
pubmed: 15498824
JAMA. 2013 Mar 6;309(9):896-908
pubmed: 23462786
Nat Med. 2012 Jul 06;18(7):1028-40
pubmed: 22772564